Sanofi Secures German Regulatory Clearance for Dynavax Acquisition
Summary
Sanofi announced that it has received German foreign direct investment clearance, a key condition for its tender offer to acquire Dynavax Technologies Corporation.
Key Events
-
German FDI Clearance Obtained
The Federal Ministry for Economic Affairs and Energy (BMWK) cleared the acquisition of Dynavax GmbH, a condition for the overall tender offer.
-
Acquisition Progresses
This clearance, effective January 29, 2026, marks another significant step towards completing Sanofi's tender offer for Dynavax Technologies, following the HSR waiting period expiration.
Analysis
This amendment signals significant progress towards the completion of Sanofi's acquisition of Dynavax Technologies. The clearance from the German Federal Ministry for Economic Affairs and Energy removes a critical regulatory condition, de-risking the transaction and moving it closer to its expected close. This follows the expiration of the HSR waiting period announced on January 28, 2026, indicating a steady progression through regulatory approvals since the initial tender offer on January 12, 2026.
At the time of this filing, SNY was trading at $46.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $111.8B. The 52-week trading range was $44.62 to $60.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.